Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Receives $280K to Support its Diagnostic Platform

NEW YORK (GenomeWeb News) – Response Biomedical said today that it has received C$283,756 (US$279,640) from the Canadian government to support its Ramp point-of-care platform.

The funding from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) will be used by Vancouver, British Columbia-based Response Biomedical for a project to improve the Ramp platform and increase the firm's ability to compete in the marketplace.

Response Biomedical did not elaborate on the project, saying only that the goal is to "improve the customer experience" with the platform.

The Ramp system consists of a reader and single-use disposable test cartridges. The Ramp Reader and Ramp 200 reader are portable scanning fluorescence quantitative analysis platforms for near-patient testing.

Clinical tests for the Ramp system are currently available for the early detection of heart attack and congestive hear failure. In the non-clinical arena, Ramp tests exists for the environmental detection of West Nile Virus, as well biodefense applications such as the on-site detection of anthrax, smallpox, ricin, and botulinum toxin.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.